Yanxia Guo
About Yanxia Guo
Yanxia Guo is a Senior Research Investigator in Immuno-Oncology at Bristol-Myers Squibb and a Senior Scientist in Translational Immunology at Janssen R&D, Johnson & Johnson.
Current Positions
Yanxia Guo is currently a Senior Research Investigator in Immuno-Oncology at Bristol-Myers Squibb. Additionally, she holds the position of Senior Scientist in Translational Immunology at Janssen R&D, a division of Johnson & Johnson. This dual role highlights her expertise and active involvement in both companies' frontline research efforts.
Professional Experience
Yanxia Guo has amassed significant experience in the field of immunology and oncology research. Before her current roles, she worked at Janssen R&D, Johnson & Johnson as a Scientist in Translational Immunology from 2015 to 2018. She also served as a Postdoctoral Research Fellow at Merck Research Labs in Boston from 2013 to 2015. Guo's professional journey demonstrates a consistent focus on advancing immunology research both in academic and industrial settings.
Educational Background
Yanxia Guo completed her Doctor of Philosophy (PhD) at Dartmouth College from 2007 to 2013. Her extensive academic training provided her with a deep understanding of immunology, shaping the foundation for her subsequent professional research roles in renowned pharmaceutical companies.
Immuno-Oncology Expertise
Yanxia Guo's career is marked by her expertise in immuno-oncology. Her roles at Bristol-Myers Squibb and Janssen R&D reflect her deep involvement in cutting-edge research aimed at understanding and treating cancer through immunological approaches. Her background in both academic research and practical application positions her as a key contributor to the advancement of immuno-oncology.
Research Contributions
Yanxia Guo has played an active role in translational immunology projects, particularly during her tenure at Janssen R&D, a part of Johnson & Johnson. Her work has contributed to bridging the gap between laboratory research and clinical applications, driving forward the development of new therapeutic strategies in the field of immuno-oncology.